Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2020.0293
EDITORIAL
|
Genomic and transcriptomic landscapes in the management of breast cancer. |
Prof. George Zografos, MD, PhD.
|
| |
Abstract
The breakthrough combination of two targeted drugs, specifically the addition of pertuzumab or neratinib to trastuzumab and chemotherapy has led to impressive oncological outcome benefits in both adjuvant/neo-adjuvant and metastatic HER2 positive breast cancer1-3. However, longer follow-up results are required to access potential higher late recurrence rates. Emerging rational research in genome and transcriptome exploration could reduce late recurrence rates for HER2 positive as well as to improve oncological outcomes of HER2 negative and triple negative breast cancer.
(Citation: Gastric & Breast Cancer 2020; 15(1): 25-30)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
